Patient Rating:

No Rating Available?

Tibor Kovacsovics, M.D.

Patient Rating:

No Rating Available?

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 585-2626 Huntsman Cancer Hospital
Clinic 2C/BMT, Blood and Marrow Transplant
1950 Circle of Hope
Salt Lake City, UT 84112
Map
(801) 585-2626 Huntsman Cancer Hospital
Hematology Clinic
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Specialties

Bio

Dr. Kovacsovics brings to the University of Utah extensive expertise in the clinical management of patients with hematologic malignancies, particularly acute leukemias. In his role at the University of Utah, Dr. Kovacsovics will serve as the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies. In his role as Associate Director of Hematologic Malignancy Clinical Research in the HCI Clinical Trials Office, he will establish a phase 1 program in hematologic malignancies, coordinate clinical research in the Division and develop a Clinical-translational Research Network suitable to carry out multicenter investigator-initiated studies in hematologic malignancies, with an emphasis on correlative science. He will also develop relationships with community practices to engage community practices in HCI-based clinical trials and increase the number of patients treated on clinical trials.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Hematology/BMT

Academic Profile

Research Interests

  • Acute Myeloid Leukemia (AML)
  • Chemotherapy
  • Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Hematology/BMT

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 213-5621 Huntsman Cancer Institute
Hematology and Hematologic Malignancies
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Dr. Kovacsovics graduated from the University of Geneva Medical School, and was a Resident in Internal Medicine at the Clinique Médicale Thérapeutique at Geneva University Hospital, Switzerland, after which he became Chief Resident at the same institution. He also completed training as a Research Assistant at the Institute of Biochemistry at the University of Lausanne, Switzerland. He then became a Clinical and Research Fellow in Medicine, Hematology-Oncology, at Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School. This was followed by positions as “Chef de Clinique” and “Médecin Associé” in the Division of Hematology at Lausanne University Hospital, Switzerland, where he set up the autologous hematopoietic stem cell transplant program. In 2004 he was recruited to the Faculty at Oregon Health Science University, where he developed a program in acute leukemia, with a focus on innovative clinical trials and molecular diagnostics. Dr. Kovacsovics has served as both principal investigator and co-investigator on numerous clinical trials and grants. Many of his clinical trials focus on new agents for treatment of acute leukemias. He is a member of multiple professional societies, and was the chairman of the Swiss Leukemia Cooperative Group (SAKK) from 2002-2004. He has published over forty peer-reviewed manuscripts, and is a regular reviewer for many top Hematology journals, including Blood, American Journal of Cancer, Haematologica, and Leukemia.

Education

Education History

Type School Degree
Fellowship Brigham and Women's Hospital
Clinical and Research Fellow in Medicine, Hematology-Oncology
Clinical Fellow
Fellowship Massachusetts General Hospital
Clinical and Research Fellow in Medicine, Hematology-Oncology
Clinical Fellow
Chief Resident Clinique Médicale Thérapeutique, Geneva University Hospital
Internal Medicine
Chief Resident
Residency Clinique Médicale Thérapeutique, Geneva University Hospital
Internal Medicine
Resident
Postdoctoral Fellowship University of Lausanne
Research Assistant, Institute of Biochemistry
Postdoctoral Fellow
Professional Medical University of Geneva Medical School
Medicine
M.D.

Publications

Selected Provider Publications

Journal Article

  1. Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Al Masri A, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH (2014). Functional integration of acute myeloid leukemia into the vascular niche.LID - 10.1038/leu.2014.109 [doi]. Leukemia.
  2. Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT (2014). Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study.LID - S2152-2650(14)00045-7 [pii]LID - 10.1016/j.clml.2014.02.003 [doi]. Clin Lymphoma Myeloma Leuk.
  3. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
  4. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013 Jan 1). KInase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
  5. Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H (2012). Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma, 53(3), 435-40.
  6. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM (2012). Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. J Clin Oncol, 30(20), 2492-9.
  7. Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G (2012). Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. Hum Pathol.
  8. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics T, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ (In Press). Phase II, Multicenter, Randomized, Open Label Trial of CPX-351 (cytarabine:daunorubicin) Liposome injection versus Cytarabine and Daunorubicin in Patients with Untreated AML 60-75 Years of Age. Blood.

Case Report

  1. Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G (2012). RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma, 53(5), 999-1002.

Clinical Trials

Video & News

Video